News

In a sense, every investor is a growth investor. Even those who are primarily seeking income enjoy when the stocks they buy increase in value. But which stocks are likely to deliver growth over the

It's been a rough start to 2025 for Merck (NYSE: MRK) shareholders following a less-than-stellar fourth-quarter earnings report. Even as the pharmaceutical giant exceeded Wall Street estimates with

There are many ways to make money on Wall Street, but some methods are a lot more reliable than others. Whether you're looking for a way to raise the stream of passive income your portfolio produces

Cancer drug specialist Exelixis (NASDAQ: EXEL) was quite the stock market star on Friday. Following news that it's making a big, shareholder-pleasing move, market players piled into the company to

Medical device manufacturer Medtronic (NYSE: MDT) is a healthcare industry stalwart. The company, based in the U.S. and Ireland, is one of the largest in its segment, developing and selling a

The U.S. Department of Justice has reportedly launched an investigation into UnitedHealth Group's (NYSE: UNH) Medicare billing practices.

Investors were shaken by the report, sending UnitedHealth

Looking for a good area in which to invest? Consider the healthcare sector. People must have healthcare. And with aging populations, the demand for healthcare products and services should grow

Image source: The Motley Fool.

Dynavax Technologies (NASDAQ: DVAX)Q4 2024 Earnings CallFeb 20, 2025, 4:30 p.m. ET

Operator

Continue reading

Source Fool.com

In this episode of the Motley Fool Scoreboard, analysts evaluate Trupanion (NASDAQ: TRUP) and its potential as a pet insurance leader. With a solid track record and a growing market, is Trupanion a

Ardelyx (NASDAQ:ARDX), a biopharmaceutical company specializing in innovative treatments for gastrointestinal and kidney diseases, released its fourth-quarter earnings report on Feb. 20. The release

In this video, I will cover the recent updates about Advanced Micro Devices (NASDAQ: AMD). Watch the short video to learn more, consider subscribing, and click the special offer link below.

*Stock

While many investors focus on a company's stock price, dividends can often be unsung heroes when it comes to making money. Dividend stocks may not be as sexy as growth stocks or get much of the same

Discrete GPUs were initially designed for use in video games and professional graphics applications, but they've now become the backbone of data centers that use them to process all sorts of

Trupanion (NASDAQ:TRUP), a leader in pet medical insurance, released its Q4 2024 earnings on February 19, 2025. The company delivered mixed results, with earnings per share (EPS) at $0.04, missing

Image source: The Motley Fool.

Karyopharm Therapeutics (NASDAQ: KPTI)Q4 2024 Earnings CallFeb 19, 2025, 8:00 a.m. ET

Operator

Continue reading

Source Fool.com

Image source: The Motley Fool.

Medtronic (NYSE: MDT)Q3 2025 Earnings CallFeb 18, 2025, 8:00 a.m. ET

Ryan Weispfenning -- Vice President and Head, Investor Relations

Continue reading

Source Fool.com

Image source: The Motley Fool.

Axsome Therapeutics (NASDAQ: AXSM)Q4 2024 Earnings CallFeb 18, 2025, 8:00 a.m. ET

Operator

Continue reading

Source Fool.com

Biotech giant Renegeron Pharmaceuticals (NASDAQ: REGN) reported its fourth-quarter and full-year 2024 earnings on Feb. 4. The company's results were strong, coming in ahead of analyst estimates

Biopharmaceutical firm Axsome Therapeutics (NASDAQ:AXSM) reported mixed fourth-quarter and full-year 2024 earnings on Tuesday, Feb. 18. The company achieved substantial revenue growth, with sales

Pfizer (NYSE: PFE) has been around for 175 years, but the company's revenue soared to its highest ever only in more recent times. Thanks to its coronavirus treatment and vaccine, the pharma giant

It's a reasonable concern for Rivian Automotive (NASDAQ: RIVN) investors that the company has no real visible catalysts in 2025. The R2 won't launch until 2026, Rivian already inked a big deal with

If you're content with market-level returns, investing in an exchange-traded fund (ETF) is the way to go. But if not, you'll need to find stocks that hold the potential to pack more punch.

Three

It's only mid-February, but as of this writing biotech company Axsome Therapeutics (NASDAQ: AXSM) is up by 55% year to date. Substantial stock-market gains over short periods aren't that rare in the

Over the course of the past few years, growth stocks have led the charge for the stock market. However, every year presents different challenges, and I think a different set of stocks -- a few that